ADD methods for aim 3
This commit is contained in:
parent
537d942b5e
commit
436eccc733
|
@ -84,6 +84,7 @@
|
||||||
\newacronym{a2b1}{A2B1}{integrin $\upalpha$1$\upbeta$1}
|
\newacronym{a2b1}{A2B1}{integrin $\upalpha$1$\upbeta$1}
|
||||||
\newacronym{a2b2}{A2B2}{integrin $\upalpha$1$\upbeta$2}
|
\newacronym{a2b2}{A2B2}{integrin $\upalpha$1$\upbeta$2}
|
||||||
\newacronym{til}{TIL}{tumor infiltrating lymphocytes}
|
\newacronym{til}{TIL}{tumor infiltrating lymphocytes}
|
||||||
|
\newacronym{nsg}{NSG}{NOD scid gamma}
|
||||||
|
|
||||||
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|
||||||
% SI units for uber nerds
|
% SI units for uber nerds
|
||||||
|
@ -1555,6 +1556,41 @@ provide these benefits.
|
||||||
|
|
||||||
\section{introduction}
|
\section{introduction}
|
||||||
\section{methods}
|
\section{methods}
|
||||||
|
|
||||||
|
\subsection{CD19-CAR T cell generation}
|
||||||
|
|
||||||
|
% TODO describe how T cells were grown for this aim
|
||||||
|
|
||||||
|
% TODO describe how the luciferase cells were generated (eg the kwong lab)
|
||||||
|
|
||||||
|
\subsection{\invivo{} therapeutic efficacy in NSG mice model}
|
||||||
|
|
||||||
|
% TODO use actual product numbers for mice
|
||||||
|
All mice in this study were male \gls{nsg} mice from Jackson Laboratories. At
|
||||||
|
day 0 (-7 day relative to T cell injection), 1e6 firefly luciferase-expressing
|
||||||
|
\product{Nalm-6 cells}{ATCC}{CRL-3273} suspended in ice-cold PBS were injected
|
||||||
|
via tail vein into each mouse. At day 7, saline or CAR T cells at the indicated
|
||||||
|
doses from either bead or DMS-expanded T cell cultures (for 14 days) were
|
||||||
|
injected into each mouse via tail vein. Tumor burden was quantified
|
||||||
|
longitudinally via IVIS Spectrum In Vivo Imaging System (Perkin Elmer). Briefly,
|
||||||
|
200ug/mice luciferin at 15 mg/ml in PBS was injected intraperitoneally under
|
||||||
|
isoflurane anesthesia into each mouse and waited for at least 10 minutes before
|
||||||
|
imaging. Mice were anesthetized again and imaged using the IVIS. Mice from each
|
||||||
|
treatment group/dose were anesthetized, injected, and imaged together, and
|
||||||
|
exposure time of the IVIS was limited to avoid saturation based on the signal
|
||||||
|
from the saline group. IVIS images were processed by normalizing them to common
|
||||||
|
minimum and maximum photon counts and total flux was estimated in terms of
|
||||||
|
photons/second. Endpoint for each mouse was determined by IACUC euthanasia
|
||||||
|
criteria (hunched back, paralysis, blindness, lethargy, and weight loss).
|
||||||
|
Mice were euthanized according to these endpoint criteria using carbon dioxide
|
||||||
|
asphyxiation.
|
||||||
|
|
||||||
|
\subsection{statistics}
|
||||||
|
|
||||||
|
For the \invivo{} model, the survival curves were created and statistically
|
||||||
|
analyzed using GraphPad Prism using the Mantel-Cox test to assess significance
|
||||||
|
between survival groups.
|
||||||
|
|
||||||
\section{results}
|
\section{results}
|
||||||
\section{discussion}
|
\section{discussion}
|
||||||
|
|
||||||
|
|
Loading…
Reference in New Issue